Published in Neurosurg Rev on June 09, 2011
Cytokine patterns in brain tumour progression. Mediators Inflamm (2013) 0.92
Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity. Clin Nucl Med (2012) 0.90
An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals. PLoS One (2015) 0.87
Induced interleukin-33 expression enhances the tumorigenic activity of rat glioma cells. Neuro Oncol (2013) 0.86
Organotypic brain slices: a model to study the neurovascular unit micro-environment in epilepsies. Fluids Barriers CNS (2013) 0.85
Transcription regulation of E-cadherin by zinc finger E-box binding homeobox proteins in solid tumors. Biomed Res Int (2014) 0.83
Interleukin-1β promotes hypoxia-induced apoptosis of glioblastoma cells by inhibiting hypoxia-inducible factor-1 mediated adrenomedullin production. Cell Death Dis (2014) 0.81
Regulation of Kir4.1 expression in astrocytes and astrocytic tumors: a role for interleukin-1 β. J Neuroinflammation (2012) 0.79
Signal transduction molecule patterns indicating potential glioblastoma therapy approaches. Onco Targets Ther (2013) 0.76
Clinical significance of tryptophan metabolism in the nontumoral hemisphere in patients with malignant glioma. J Nucl Med (2014) 0.76
Imaging cerebral tryptophan metabolism in brain tumor-associated depression. EJNMMI Res (2015) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 25.63
Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature (2003) 20.48
TGF-beta signal transduction. Annu Rev Biochem (1998) 17.83
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 15.15
Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 13.46
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Regulation of immune responses by TGF-beta. Annu Rev Immunol (1998) 8.01
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science (1990) 7.18
Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73
TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol (1994) 6.00
CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med (1994) 5.90
IL-13 effector functions. Annu Rev Immunol (2001) 5.51
Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol (2003) 5.36
Mast cell lines produce lymphokines in response to cross-linkage of Fc epsilon RI or to calcium ionophores. Nature (1989) 5.10
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
T(H)1 cells control themselves by producing interleukin-10. Nat Rev Immunol (2007) 3.65
Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol (2005) 3.48
Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol (2008) 3.40
Selective contribution of IFN-alpha/beta signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc Natl Acad Sci U S A (2003) 3.29
Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev (2006) 3.14
CNS immune privilege: hiding in plain sight. Immunol Rev (2006) 3.13
Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev (1997) 3.11
Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev (1995) 2.92
Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab Invest (1993) 2.89
Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol (2010) 2.71
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med (2000) 2.69
Type I interferons produced by dendritic cells promote their phenotypic and functional activation. Blood (2002) 2.59
2. Cytokines and chemokines. J Allergy Clin Immunol (2003) 2.54
Immunity to homologous grafted skin; the fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol (1948) 2.53
Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev (2008) 2.52
SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res (2004) 2.35
Immunologically privileged sites. Adv Immunol (1977) 2.35
Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res (2003) 2.27
Microglia function in brain tumors. J Neurosci Res (2005) 2.18
Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res (2002) 2.05
Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol (2010) 2.04
Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today (1992) 1.96
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol (2006) 1.95
Interleukin-10 suppression of myeloid cell activation--a continuing puzzle. Immunology (2004) 1.95
Characterization of the human B cell stimulatory factor 1 receptor. J Exp Med (1987) 1.92
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol (1998) 1.81
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res (2001) 1.73
Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (1988) 1.65
T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-beta. EMBO J (1987) 1.59
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology (2006) 1.54
Mechanisms of Interferon-alpha induced apoptosis in malignant cells. Oncogene (2002) 1.50
Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin Cancer Res (1995) 1.50
Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumour resection and postoperative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir (Wien) (1994) 1.45
IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol (1999) 1.45
Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. J Immunol (1995) 1.42
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides (2007) 1.40
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer (2000) 1.36
SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol Cancer Ther (2004) 1.35
Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination. Hum Immunol (2008) 1.31
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res (2005) 1.27
Safety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant glioma. J Neurooncol (2003) 1.26
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg (1995) 1.25
Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol (2000) 1.22
Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev (2005) 1.19
Interleukin-10-induced CD8 cell proliferation. Immunology (1999) 1.16
Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2. Cancer Immunol Immunother (1997) 1.16
Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J Neurooncol (2003) 1.16
Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene (2001) 1.15
Combined HSV-TK/IL-2 gene therapy in patients with recurrent glioblastoma multiforme: biological and clinical results. Cancer Gene Ther (2005) 1.11
Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol (2007) 1.10
Immune infiltration of spontaneous mouse astrocytomas is dominated by immunosuppressive cells from early stages of tumor development. Cancer Res (2010) 1.07
Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer (1995) 1.06
Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol (1999) 1.06
TGF-beta in neural stem cells and in tumors of the central nervous system. Cell Tissue Res (2007) 1.06
High affinity binding of human interleukin 4 to cell lines. Biochem Biophys Res Commun (1987) 1.06
Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol (2002) 1.05
Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin. Mol Cancer Ther (2008) 1.05
The involvement of TNF-alpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol (2001) 1.05
A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol Ther (2008) 1.03
Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J Leukoc Biol (1999) 1.01
Molecular cloning of a cDNA encoding the human interleukin 4 receptor. Int Immunol (1990) 1.00
Identification of interleukin 4 receptor-associated proteins and expression of both high- and low-affinity binding on human lymphoid cells. Eur J Immunol (1989) 1.00
Messenger RNA expression of the immunosuppressive cytokine IL-10 in human gliomas. Am J Pathol (1995) 1.00
Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas. Clin Exp Immunol (1996) 0.99
Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther (1999) 0.98
Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes. Neurosurg Focus (2000) 0.98
Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol (2008) 0.97
Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial. Cancer Res (1986) 0.96
Induction of apoptosis and immune response by all-trans retinoic acid plus interferon-gamma in human malignant glioblastoma T98G and U87MG cells. Cancer Immunol Immunother (2006) 0.96
Functional repertoire of dendritic cells generated in granulocyte macrophage-colony stimulating factor and interferon-alpha. J Leukoc Biol (2003) 0.95
Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer (1997) 0.95
The interleukin-4-related lymphokines and their binding to hematopoietin receptors. J Biol Chem (1992) 0.95
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol (2007) 0.94
Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma. J Neurooncol (2006) 0.93
Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther (2003) 0.93
Safety of intraparenchymal convection-enhanced delivery of cintredekin besudotox in early-phase studies. Neurosurg Focus (2006) 0.91
Emerging role of combination of all-trans retinoic acid and interferon-gamma as chemoimmunotherapy in the management of human glioblastoma. Neurochem Res (2007) 0.91
Treatment of intracranial glioma with in situ interferon-gamma and tumor necrosis factor-alpha gene transfer. Cancer Gene Ther (2002) 0.89
A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med (2008) 0.88
Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma. Int J Radiat Oncol Biol Phys (1998) 0.88
Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas. J Neurooncol (2006) 0.88
Intraoperative tractography and motor evoked potential (MEP) monitoring in surgery for gliomas around the corticospinal tract. World Neurosurg (2010) 2.13
Selective propofol injection into the M1 segment of the middle cerebral artery (MCA Wada test) reduces adverse effects and enhances the reliability of the Wada test for determining speech dominance. World Neurosurg (2011) 2.04
Variable DNA methylation patterns associated with progression of disease in hepatocellular carcinomas. Carcinogenesis (2008) 1.57
Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy (2012) 1.55
A novel method of intracranial injection via the postglenoid foramen for brain tumor mouse models. J Neurosurg (2011) 1.45
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy. Leuk Lymphoma (2011) 1.43
Papillary glioneuronal tumor with a high proliferative component and minigemistocytes in a child. Neuropathology (2014) 1.38
IFN-beta down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res (2005) 1.27
Intradural cranial chordoma. World Neurosurg (2009) 1.27
Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int (2012) 1.23
Intravenously transplanted human neural stem cells migrate to the injured spinal cord in adult mice in an SDF-1- and HGF-dependent manner. Neurosci Lett (2007) 1.18
Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study. Cancer (2010) 1.18
Glioma-initiating cells and molecular pathology: implications for therapy. Brain Tumor Pathol (2011) 1.17
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. Neuro Oncol (2006) 1.11
The global DNA methylation surrogate LINE-1 methylation is correlated with MGMT promoter methylation and is a better prognostic factor for glioma. PLoS One (2011) 1.11
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer (2008) 1.09
Heat shock protein 70 expression induces antitumor immunity during intracellular hyperthermia using magnetite nanoparticles. Cancer Immunol Immunother (2003) 1.08
Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen. Cancer Sci (2010) 1.08
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation. Tumour Biol (2014) 1.02
Interferon-beta gene therapy for cancer: basic research to clinical application. Cancer Sci (2004) 1.02
Efficacy of temozolomide is correlated with 1p loss and methylation of the deoxyribonucleic acid repair gene MGMT in malignant gliomas. Neurol Med Chir (Tokyo) (2007) 1.00
The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. Mol Cancer Res (2009) 0.98
Adipsia increases risk of death in patients with central diabetes insipidus. Endocr J (2013) 0.98
Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma. Cancer Res (2013) 0.97
Induction of oligodendrogenesis in glioblastoma-initiating cells by IFN-mediated activation of STAT3 signaling. Cancer Lett (2009) 0.97
Stem cells from human exfoliated deciduous tooth-derived conditioned medium enhance recovery of focal cerebral ischemia in rats. Tissue Eng Part A (2012) 0.96
Brain metastases from apocrine carcinoma of the scalp: case report. J Neurooncol (2005) 0.96
A combination of IFN-beta and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulation. Cancer Chemother Pharmacol (2007) 0.94
Immunohistochemical analysis-based proteomic subclassification of newly diagnosed glioblastomas. Cancer Sci (2012) 0.93
Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther (2003) 0.93
Injectable bone tissue engineering using expanded mesenchymal stem cells. Stem Cells (2013) 0.93
Contribution of microRNA-1275 to Claudin11 protein suppression via a polycomb-mediated silencing mechanism in human glioma stem-like cells. J Biol Chem (2012) 0.91
Effectiveness of plasma treatment on gastric cancer cells. Gastric Cancer (2014) 0.91
Magnetic resonance fluid dynamics for intracranial aneurysms--comparison with computed fluid dynamics. Acta Neurochir (Wien) (2012) 0.91
p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery (2009) 0.90
Cavernous sinus thrombophlebitis caused by porphyromonas gingivalis with abscess formation extending to the orbital cavity. Case report. Neurol Med Chir (Tokyo) (2009) 0.89
A novel pressure sensor with an optical system for coil embolization of intracranial aneurysms. Laboratory investigation. J Neurosurg (2009) 0.89
Management and survival of pineoblastoma: an analysis of 34 adults from the brain tumor registry of Japan. Neurol Med Chir (Tokyo) (2005) 0.89
Early recovery and better evacuation rate in neuroendoscopic surgery for spontaneous intracerebral hemorrhage using a multifunctional cannula: preliminary study in comparison with craniotomy. J Stroke Cerebrovasc Dis (2010) 0.88
Neurosurgical robotic system for brain tumor removal. Int J Comput Assist Radiol Surg (2010) 0.88
A multicenter phase I trial of interferon-beta and temozolomide combination therapy for high-grade gliomas (INTEGRA Study). Jpn J Clin Oncol (2008) 0.88
A phase I clinical trial of interferon-beta gene therapy for high-grade glioma: novel findings from gene expression profiling and autopsy. J Gene Med (2008) 0.88
Effective solitary hyperthermia treatment of malignant glioma using stick type CMC-magnetite. In vivo study. J Neurooncol (2002) 0.88
Type I interferon inhibits astrocytic gliosis and promotes functional recovery after spinal cord injury by deactivation of the MEK/ERK pathway. J Neurotrauma (2009) 0.88
Epigenetic subclassification of meningiomas based on genome-wide DNA methylation analyses. Carcinogenesis (2011) 0.88
Malignant transformation-related genes in meningiomas: allelic loss on 1p36 and methylation status of p73 and RASSF1A. J Neurosurg (2007) 0.88
Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem Biophys Res Commun (2013) 0.87
Clinical use of (11)C-methionine and (18)F-FDG-PET for germinoma in central nervous system. Ann Nucl Med (2013) 0.87
A multicenter phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): the final report. J Neurooncol (2011) 0.86
The free-radical scavenger edaravone restores the differentiation of human neural precursor cells after radiation-induced oxidative stress. Neurosci Lett (2007) 0.86
Epigenetic dysregulation in glioma. Cancer Sci (2014) 0.85
Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. J Neurooncol (2008) 0.85
Human gene therapy for malignant gliomas (glioblastoma multiforme and anaplastic astrocytoma) by in vivo transduction with human interferon beta gene using cationic liposomes. Hum Gene Ther (2004) 0.85
A free-radical scavenger protects the neural progenitor cells in the dentate subgranular zone of the hippocampus from cell death after X-irradiation. Neurosci Lett (2010) 0.84
A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation. Biochem Biophys Res Commun (2013) 0.83
Gene therapy for high-grade glioma. Neurol Med Chir (Tokyo) (2010) 0.83
Progressively unstable c2 spondylolysis requiring spinal fusion: case report. Neurol Med Chir (Tokyo) (2014) 0.82
Posterior fixation for atlantoaxial subluxation in a case with complex anomaly of persistent first intersegmental artery and assimilation in the C1 vertebra. Neurol Med Chir (Tokyo) (2013) 0.82
Fenestration of a supraclinoid internal carotid artery associated with dual aneurysms: case report. Neurosurgery (2011) 0.82
Primary angiitis of the central nervous system mimicking tumor-like lesion--case report. Neurol Med Chir (Tokyo) (2011) 0.82
Aurora-B dysfunction of multinucleated giant cells in glioma detected by site-specific phosphorylated antibodies. J Neurosurg (2004) 0.82
Endoscopic biopsy for lesions located in the parenchyma of the brain: preoperative planning based on stereotactic methods. Technical note. Neurol Med Chir (Tokyo) (2012) 0.82
[Efficacy and safety of monotherapy with temozolomide in patients with anaplastic astrocytoma at first relapse--a phase II clinical study]. Gan To Kagaku Ryoho (2006) 0.82
The role of PLK1-phosphorylated SVIL in myosin II activation and cytokinetic furrowing. J Cell Sci (2013) 0.82
Rhabdoid glioblastoma in a child: case report and literature review. Brain Tumor Pathol (2011) 0.82
Clinical indications for high-field 1.5 T intraoperative magnetic resonance imaging and neuro-navigation for neurosurgical procedures. Review of initial 100 cases. Neurol Med Chir (Tokyo) (2009) 0.81
Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305). Cancer Chemother Pharmacol (2012) 0.81
Epigenetic aberrations and therapeutic implications in gliomas. Cancer Sci (2010) 0.81
Correlation between quantified promoter methylation and enzymatic activity of O6-methylguanine-DNA methyltransferase in glioblastomas. Tumour Biol (2012) 0.81
Intraventricular chordoid meningioma presenting with Castleman disease due to overproduction of interleukin-6. Case report. J Neurosurg (2005) 0.81
The 'one and a half round microcatheterization technique' for stent-assisted coil embolization of intracranial aneurysm: technical case series. J Neurointerv Surg (2013) 0.80
Identification of a human leukocyte antigen-A24-restricted T-cell epitope derived from interleukin-13 receptor alpha2 chain, a glioma-associated antigen. J Neurosurg (2008) 0.80